Eurofins-Cerep SA (FR:ALECR) has released an update.
Claim 55% Off TipRanks
- Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis.
- Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter
Eurofins-Cerep SA reported a decrease in revenue for the first semester of 2024, down by 7.68% from the previous year, amid a contracting drug discovery market. Despite this, the company saw a positive financial result from cash investments and exchange rates, as well as progress in R&D with new pharmacological test applications and a biophysics platform for drug research. Looking ahead, the firm anticipates that renewed and developing contracts will mitigate turnover declines in the latter half of 2024.
For further insights into FR:ALECR stock, check out TipRanks’ Stock Analysis page.